Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KGfiledCriticalBoehringer Ingelheim Pharma GmbH Co KG
Priority to ARP100102603priorityCriticalpatent/AR077758A2/en
Publication of AR077758A2publicationCriticalpatent/AR077758A2/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Abstract
Un método para la preparacion de telmisartan sustancialmente amorfo que comprende: a) preparar una solucion acuosa que comprende telmisartan y al menos un agente básico, y b) secar por rocío dicha solucion acuosa para obtener un granulado secado por rocío.A method for the preparation of substantially amorphous telmisartan comprising: a) preparing an aqueous solution comprising telmisartan and at least one basic agent, and b) drying said aqueous solution by dew to obtain a spray-dried granulate.
ARP1001026032010-07-162010-07-16
A METHOD FOR THE PREPARATION OF TELMISARTAN SUBSTANTIALLY AMORFO
PendingAR077758A2
(en)
Composition comprising a solution of hypochlorous acid (hocl); process for preparing aqueous solution of hocl; use as an antimicrobial agent, as a cleaning agent or sterilizer; material impregnated with the composition and use to sterilize objects.
Compounds derived from 4-isopropylphenylglucitol, sglt1 inhibitors; pharmaceutical preparation; and its use as an agent to improve postprandial hyperglycemia and as a prophylactic or therapeutic agent for diabetes.
Process for preparing a pharmaceutical composition comprising i) providing a first combination comprising a peptide proteasome inhibitor compound, one or more cyclodextrins and water, and ii) contacting the first combination with an acid to form a second combination; pharmaceutical composition
Aqueous acid formulation comprising a first fluorocarbon linked peptide; method to obtain said formulation; use of said formulation to treat or prevent pathogenic infection, an autoimmune disease or cancer.